Partner, Hellman & Friedman
Appears in 1 story
Sponsor-side advocate for the Medline investment thesis
Medline's Nasdaq arrival as MDLN quickly turned from “biggest IPO of 2025” into a live market verdict. Shares jumped roughly 41% in their first session, pushing the company into a roughly $50B+ valuation almost immediately.
Updated May 15
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
